e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 28, 2008
Artes Medical, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33205
|
|
33-0870808 |
(State or Other
Jurisdiction of
Incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.) |
5870 Pacific Center Boulevard
San Diego, California 92121
(Address of Principal Executive Offices, with zip code)
(858) 550-9999
(Registrants telephone number, including area code)
n/a
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 5.02. |
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers |
On February 28, 2008, the Compensation Committee (the Committee) of the Board of Directors
(the Board) of Artes Medical, Inc. (the Company) met and fixed the base salaries and target
bonus amounts for the Companys executive officers for fiscal
year 2008. The base salaries and the
target bonus amounts for the Companys principal executive officer, principal financial officer and
named executive officers are as follows:
|
|
|
|
|
|
|
|
|
Name and Title |
|
Base Salary |
|
Target Bonus Amount |
Christopher J. Reinhard, Executive
Chairman of the Board |
|
$ |
150,000 |
|
|
$ |
75,000 |
|
Diane S. Goostree, President and
Chief Executive Officer |
|
|
325,000 |
|
|
|
162,500 |
|
Peter C. Wulff, Executive Vice
President and Chief Financial Officer |
|
|
250,000 |
|
|
|
87,500 |
|
Larry J. Braga, Vice President -
Manufacturing |
|
|
225,000 |
|
|
|
67,500 |
|
In
accordance with the Companys Annual Bonus Incentive Plan, 50%
of the target bonus amounts for
these executive officers will be based on the Companys achievement of corporate goals during
fiscal year 2008 and the remaining 50% will be based on the individual performance of the executive
officer during the year.
The Board also granted stock options to the executive officers on February 28, 2008 under the
Companys 2006 Equity Incentive Plan (the Plan). The stock grants for the Companys principal
executive officer, principal financial officer and named executive officers are as follows:
|
|
|
|
|
|
|
Number of |
Name and Title |
|
Shares |
Christopher J. Reinhard, Executive Chairman of the Board |
|
|
|
|
Diane S. Goostree, President and Chief Executive Officer |
|
|
93,024 |
|
Peter C. Wulff, Executive Vice President and Chief
Financial Officer |
|
|
26,391 |
|
Larry J. Braga, Vice President Manufacturing |
|
|
40,683 |
|
The stock options have an exercise price of $2.20 per share, the closing sale price of the
Companys common stock as reported on the Nasdaq Global Market on the grant date. The stock options
vest over four years, with 25% of the option shares vesting 12 months after the grant date, and
the remaining 75% of the option shares vesting in 36 equal monthly
installments thereafter. The stock options will
automatically
terminate on February 27, 2009, without any vesting, if the Company fails to satisfy a revenue milestone
set by the Committee for fiscal year 2008. The stock options may be accelerated in the event of
certain corporate transactions as provided in the Plan.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated:
March 5, 2008
|
|
|
|
|
|
ARTES MEDICAL, INC.
|
|
|
By: |
/s/
Karla R. Kelly |
|
|
|
Karla R. Kelly
Chief Legal Officer, General Counsel and |
|
|
|
Corporate Secretary |
|
|